Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

SNSP113

Phase One

Phase One

Therapeutic Approach

Anti-Infective

SNSP113 is a new inhaled glycopolymer, a type of molecule being developed to treat infection and inflammation in the lungs. When bacteria infect the lungs of people with CF, it can form structures called biofilms. Biofilms make bacteria more resistant to antibiotics. SNSP113 helps break up biofilms in the lungs, allowing antibiotics to fight bacteria more effectively. SNSP113 may also make mucus thinner and less sticky, reducing inflammation and improving airway clearance. 

Status

A phase 1a study to test the safety of SNSP113 in healthy adults has been completed. Future studies will test the safety and tolerability of SNSP113 in people with CF. 

Sponsor

This program is sponsored by Synspira and partially funded by the Cystic Fibrosis Foundation. 



Contact us about SNSP113 >